As we move through 2026, the industry is undergoing an "Economic Realignment." This year, the Pulmonary Arterial Hypertension Market has achieved a "Generic Acceleration" milestone, with patents on several major prostacyclins expiring, leading to a projected 11.28% CAGR for generic alternatives. This is proving essential for the 2026 "Global Access" goal, as it finally brings high-tier...